Hodgkin's disease of the liver; prognosis and possible indications for radiotherapy.
A retrospective analysis of 56 patients presenting with Hodgkin's disease involving the liver between 1970 and 1984 revealed a 10-year survival probability of 44%. The actuarial 10-year continuous progression free survival was 42%. Presentation variables predicting for relapse in the liver included hepatomegaly (P less than 0.025) or focal lesions on isotope, ultrasound or CT scan (P less than 0.01). These factors may define a context for investigation of adjuvant hepatic irradiation following chemotherapy.
O'Brien
P
P
Department of Radiotherapy and Oncology, Royal Marsden Hospital, Sutton, Surrey, UK.
Crow
J
J
Brada
M
M
Ashley
S
S
Horwich
A
A
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002699:Chlorambucil / Q000008:administration & dosage; D002985:Clinical Protocols; D006689:Hodgkin Disease / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000528:radiation effects*; D008113:Liver Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D008466:Mechlorethamine / Q000008:administration & dosage; D009367:Neoplasm Staging; D011239:Prednisolone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D011379:Prognosis; D011879:Radiotherapy Dosage; D012074:Remission Induction; D012189:Retrospective Studies; D013997:Time Factors; D014747:Vinblastine / Q000008:administration & dosage
D002699:Chlorambucil; D011344:Procarbazine; D008466:Mechlorethamine; D014747:Vinblastine; D011239:Prednisolone